Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27647766
DOI
10.1002/ejhf.640
Knihovny.cz E-resources
- Keywords
- Bioenergetics, Heart failure, Iron deficiency, Metabolism, Mitochondria, Reactive oxygen species,
- MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Myocardium metabolism MeSH
- Aged MeSH
- Mitochondria, Heart metabolism MeSH
- Heart Failure metabolism physiopathology surgery MeSH
- Case-Control Studies MeSH
- Heart Transplantation MeSH
- Iron metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Iron MeSH
AIMS: Iron replacement improves clinical status in iron-deficient patients with heart failure (HF), but the pathophysiology is poorly understood. Iron is essential not only for erythropoiesis, but also for cellular bioenergetics. The impact of myocardial iron deficiency (MID) on mitochondrial function, measured directly in the failing human heart, is unknown. METHODS AND RESULTS: Left ventricular samples were obtained from 91 consecutive HF patients undergoing transplantation and 38 HF-free organ donors (controls). Total myocardial iron content, mitochondrial respiration, citric acid cycle and respiratory chain enzyme activities, respiratory chain components (complex I-V), and protein content of reactive oxygen species (ROS)-protective enzymes were measured in tissue homogenates to quantify mitochondrial function. Myocardial iron content was lower in HF compared with controls (156 ± 41 vs. 200 ± 38 µg·g-1 dry weight, P < 0.001), independently of anaemia. MID (the lowest iron tercile in HF) was associated with more extensive coronary disease and less beta-blocker usage compared with non-MID HF patients. Compared with controls, HF patients displayed reduced myocardial oxygen2 respiration and reduced activity of all examined mitochondrial enzymes (all P < 0.001). MID in HF was associated with preserved activity of respiratory chain enzymes but reduced activity of aconitase and citrate synthase (by -26% and -15%, P < 0.05) and reduced expression of catalase, glutathione peroxidase, and superoxide dismutase 2. CONCLUSION: Myocardial iron content is decreased and mitochondrial functions are impaired in advanced HF. MID in HF is associated with diminished citric acid cycle enzyme activities and decreased ROS-protecting enzymes. MID may contribute to altered myocardial substrate use and to worsening of mitochondrial dysfunction that exists in HF.
Department of Bioenergetics Institute of Physiology Academy of Sciences Prague Czech Republic
Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA
Department of Transplantation and Tissue Bank University Hospital in Motol Prague Czech Republic
References provided by Crossref.org
Iron Deficiency in Patients with Advanced Heart Failure